Focused On-demand Library for Lysophosphatidic acid receptor 6

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P43657

UPID:

LPAR6_HUMAN

Alternative names:

Oleoyl-L-alpha-lysophosphatidic acid receptor; P2Y purinoceptor 5; Purinergic receptor 5; RB intron encoded G-protein coupled receptor

Alternative UPACC:

P43657; A4FTW9; B3KVF2; F2YGU4; O15133; Q3KPF5; Q53FA0; Q5VW44; Q7Z3S0; Q7Z3S6

Background:

Lysophosphatidic acid receptor 6, also known as Oleoyl-L-alpha-lysophosphatidic acid receptor, plays a pivotal role in the maintenance of hair growth and texture by binding to oleoyl-L-alpha-lysophosphatidic acid (LPA). Its activation involves intracellular cAMP, highlighting its significance in cellular signaling pathways. This receptor is encoded by the gene with the accession number P43657 and is alternatively named P2Y purinoceptor 5 and Purinergic receptor 5.

Therapeutic significance:

The receptor's malfunction is linked to Woolly hair autosomal recessive 1 with or without hypotrichosis and Hypotrichosis 8, diseases characterized by abnormal hair growth and texture. Understanding the role of Lysophosphatidic acid receptor 6 could open doors to potential therapeutic strategies for these hair shaft disorders, offering hope for targeted treatments.